Concarlo Therapeutics

We are excited to share that Krishna Allamneni, our EVP and Chief Development Officer, will serve as a judge at the Autoimmune and Cell Therapy Symposium. This event features experts who are pioneering advancements in autoimmune and cell therapy. We have a special promo code for our community: CONCARLO20OFF for 20% off. We appreciate your support and hope to see you at the event on March 26, 2025! #Biotech #AutoImmuneAndCellTherapySymposium #Aquillius

Celebrating the women and girls in science who are driving discovery, advancing innovation, and breaking barriers! ?????????? ?????????????????????????? ?????????? ?????? ?????????? ???? ?????????????? ??????. ?? #WomenInScience #STEM #GirlsInSTEM #InternationalDayofWomenandGirlsinScience #Concarlo

There is now lots of preclinical data supporting the need to drug both CDK4/6 and CDK2 in order to overcome resistance to CDK4/6 inhibitors, like palbociclib, ribociclib or abemaciclib. And now there are lots of newer CDK2 inhibitors in the preclinical and clinical pipeline, as summarized in this review by House, et. al, (https://lnkd.in/ebtuWtig) and in the table below. The issue, however, that as monotherapies, most of these CDK2i have poor responses, reinforcing that both halves of the G1 CDK see-saw (CDK4/6 and CDK2) have to be drugged. Combining monotherapy CDK4/6 and CDK2 inhibitors is one approach, but this may lack coordination, resulting in suboptimal efficacy, and potential combined toxicity due to non-overlapping adverse effects, as is being seen in early reports of Ph1a data. It’s time to look at other ways to inhibit these three critical CDKs, and that’s where Concarlo’s approach to inhibit p27, the master regulator of CDK2/4/6 comes in. https://lnkd.in/e5PnYwqN Reach out to learn more! https://concarlo.com #novelcancertargets #concarlo #cancerresearch #breastcancer

Concarlo Therapeutics is developing first-in-class small molecule p27 inhibitors to target CDK4/6 inhibitor-resistant breast cancer. There is a lot of activity in this space and Concarlo's approach capitalized on >25 years of scientific research demonstrating that targeting p27 is an effective and tolerable way to inhibit CDK2/4/6 simultaneously. Reach out and let's find a time to connect at?#JPM2025!

Our EVP, Chief Development Officer, Krishna Allamneni, will be featured in a fireside chat at R&D Procurement & Outsourcing in Biopharma Summit West tomorrow. Don't miss the chance to catch her session!? Fireside Chat: Strategic Procurement and Outsourcing: Driving Operational Excellence in Early-Stage Biopharma December 12th, 12:30 PM https://lnkd.in/eMSdWn25

?? We are excited to share this article written by our founder & CEO, Stacy Blain in Drug Discovery & Development! It highlights the importance of ???????????????? ?????? ???? ?????????????? ????????/??/?? ?????????????????and how this novel approach could shape the future of the industry. Check out her article and see how Concarlo Therapeutics' inhibitors and its focus on p27 bring true innovation to the field. #Oncology #CancerResearch #p27Inhibitor #TargetedTherapies #ConcarloTherapeutics #SmallMolecule #CDK4 #CDK2 https://lnkd.in/e5PnYwqN

Exciting times in oncology with Roche’s inavolisib, a PI3K inhibitor, advancing breast cancer therapy. ??? The FDA has approved inavolisib (Itovebi, Genentech, Inc.) in combination with palbociclib and fulvestrant for adults with endocrine-resistant, PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative advanced breast cancer. This is a significant step forward for patients with locally advanced or metastatic breast cancer, offering a new option where previous therapies have failed. ? While PI3K targeting shows potential, it's vital to explore alternative, more selective pathways for patients with drug-resistant cancers. At Concarlo Therapeutics, we're pushing forward with our p27 inhibitor, targeting the master regulator of cell cycle that drives tumor growth. We believe our approach could lead to fewer side effects and broader applications across a multitude of cancer types modulated by p27. ??? ? Looking forward to continued progress as we work to revolutionize cancer therapy. ???? ? #Oncology #BreastCancer #CancerResearch #BiotechInnovation #p27Inhibitor #TargetedTherapies #ConcarloTherapeutics #CancerCare https://lnkd.in/gxCufaRj

New Treatment Options The recent development in subclassifying HER2-negative breast cancer into HER2-low and HER2-ultralow represents a significant shift in the treatment landscape. With therapies like Enhertu now demonstrating responses in these newly defined patient groups, approximately 90% of patients with #MetastaticeBreastCancer could potentially benefit. While still a form of chemotherapy, sequencing Enhertu’s use will play a key role in optimizing patient outcomes, offering another vital option for those affected. This evolution in treatment closely aligns with Concarlo Therapeutics' mission to advance personalized cancer care. We focus on innovation in safer, more effective and durable therapies for patients with metastatic breast cancer with p27 targeted approaches. ? ? #ImproveOutcomes #BreastCancer #BreastCancerAwarenessMonth #BCAM #EmpowermentThroughInnovation https://lnkd.in/eCPt5g4k?

Reflecting on last year’s insights from our CEO, Stacy Blain: "Metastatic breast cancer remains an indomitable foe, but the incessant progress in research and treatment offers hope to those ensnared by the grip of this devastating disease. Awareness, advocacy, and financial support are not optional but rather essential in the pursuit of improving the lives of MBC patients and, ultimately, in the quest to unearth a cure."? Read the full article on Fempower Health. ? https://lnkd.in/eb3F58C8 #MBCAwarenessDay #MetastaticBreastCancerAwarenessDay #BreastCancerAwarenessMonth?

New Treatment Options #Ribociclib, Novartis’ CDK4/6 inhibitor, has now been FDA approved as adjuvant treatment for people diagnosed with HR+/HER2- stage II and III early breast cancer. Previously, Ribocicib had only been approved for advanced stage breast cancer patients. This approval represents a new choice for patients to manage the potential progression of their disease. #PatientEmpowerment #EarlyBreastCancer #BreastCancerAwarenessMonth?#BCAM https://lnkd.in/gBRWwM_Z?